As the global incidence of inflammatory bowel disease (IBD) continues to rise, innovative strategies for early identification, prevention, and treatment are urgently needed. The PROMISE (PRediction and PRevention through Omics, Microbiome, Immune System, and Environment) Consortium, is a collaborative initiative led by the Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital in Toronto, and Massachusetts General Hospital. Supported by Helmsley, PROMISE aims to advance prediction, prevention, and improved outcomes for individuals at risk of developing IBD.
Recently, PROMISE convened an international group of multidisciplinary experts, patient advocates, and individuals with IBD to create a roadmap toward prevention–focused strategies and interventions. The group also engaged with Dr. Carla Greenbaum, a leading expert in type 1 diabetes prevention, to explore cross-disease learnings.
Their roadmap has now been published in Gastroenterology—marking an important step toward a future where IBD can be predicted and prevented. Read the full white paper.
